目的 觀察蓮芪膠囊聯(lián)合TP方案治療晚期食管癌的臨床療效。方法 選取2016年3月—2021年1月河南科技大學(xué)第一附屬醫(yī)院腫瘤內(nèi)科接收的120例晚期食管癌患者，所有患者采用信封抽簽法分為對照組和治療組，各60例。對照組第1天靜脈滴注紫杉醇注射液，175 mg/m²加入500 mL生理鹽水溶液中，3 h內(nèi)完成；第2天靜脈滴注順鉑注射液，75 mg/m²加入500 mL生理鹽水溶液中，3 h內(nèi)完成。治療組在對照組的基礎(chǔ)上口服蓮芪膠囊，3粒/次，3次/d。3周為1個治療周期，治療4個周期。觀察兩組療效，比較血清腫瘤標(biāo)志物、T淋巴細(xì)胞亞群、EORTC生命質(zhì)量測定量表（QLQ-C30）評分、卡氏（KPS）評分。結(jié)果 治療后，治療組的客觀緩解率、疾病控制率均高于對照組（P<0.05）。治療后，兩組QLQ-C30、KPS評分升高（P<0.05），且治療組QLQ-C30、KPS評分高于對照組（P<0.05）。治療后，兩組血清癌胚抗原（CEA）、鱗狀細(xì)胞癌抗原（SCC-Ag）、細(xì)胞角蛋白19片段（CYFRA21-1）水平均顯著下降（P<0.05），且治療組血清CEA、SCC-Ag、CYFRA21-1水平低于對照組（P<0.05）。治療后，兩組CD3⁺、CD4⁺、CD4⁺/CD8⁺下降，CD8⁺升高（P<0.05），且治療后治療組CD3⁺、CD4⁺、CD4⁺/CD8⁺低于對照組，CD8⁺高于對照組（P<0.05）。結(jié)論 蓮芪膠囊聯(lián)合TP方案治療晚期食管癌可促進生活質(zhì)量改善，有效降低血清腫瘤標(biāo)志物水平，調(diào)節(jié)免疫功能，具有較好的臨床應(yīng)用價值。

Objective To observe the clinical effect of Lianqi Capsules combined with TP chemotherapy scheme in treatment of advanced esophageal cancer. Methods Patients (120 cases) with advanced esophageal cancer in Department of Oncology of the First Affiliated Hospital of Henan University of Science and Technology from March 2016 to January 2021 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Paclitaxel Injection at the first day, 175 mg/m² added into normal saline 500 mL, completed infusion within 3 h; and patients in the control group were iv administered with Cis-platin Injection at the second day, 75 mg/m² added into normal saline 500 mL, completed infusion within 3 h. Patients in the treatment group were po administered with Lianqi Capsules on the basis of the control group, 3 grains/time, three times daily. Three weeks was one treatment cycle, and patients in two groups were treated for 4 treatment cycles. After treatment, the clinical efficacies were evaluated, and serum tumor markers, T lymphocyte subsets, QLQ-C30 scores, and KPS scores in two groups were compared. Results After treatment, the objective remission rate and disease control rate in the treatment group were higher than those in the control group (P < 0.05). After treatment, the QLQ-C30 scores and KPS scores in two groups were significantly increased (P < 0.05), and the QLQ-C30 scores and KPS scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of CEA, SCC-Ag, and CYFRA21-1 in two groups were significantly decreased (P < 0.05), and the serum levels of CEA, SCC-Ag, and CYFRA21-1 in the treatment group were lower than those in the control group (P < 0.05). After treatment, the CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were decreased, but the CD8⁺ in two groups were increased (P < 0.05). After treatment, the CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the treatment group were lower than those in the control group, but the CD8⁺ in the treatment group was higher than those in the control group (P < 0.05). Conclusion Lianqi Capsules combined with TP chemotherapy scheme in treatment of advanced esophageal cancer can promote the improvement of quality of life, effectively reduce the level of serum tumor markers, regulate immune function, which has a good clinical application value.

R979.1

河南省醫(yī)學(xué)科技攻關(guān)計劃聯(lián)合共建項目（2018020297）